Gynecological Carcinosarcoma (GCS) is a rare and aggressive cancer found primarily in the ovaries and uterus and can also originate in the fallopian tubes and vagina. GCS, is also known as MMMT or Malignant Mixed Mullerian Tumor. Carcinosarcoma is unique in that it contains two types of cells: Carcinomatous (epithelial tissue) and sarcomatous (connective tissue). GCS is rare. Fewer than 1,000 cases of GCS are diagnosed each year. Because carcinosarcoma is so rare, there has been limited research results and no cures or effective treatments for us. In order for us to have a fighting chance, we must aggressively support new and ongoing research so that not one more woman will die from this rotten cancer.
During the course of the last year, The GCS Project has been in collaboration with several leading cancer centers to develop a resource to support general questions regarding Gynecological Carcinosarcoma. In an effort to provide more timely responses to inquiries, The GCS Project has engaged the OSF On Call to answer phone calls on The GCS Project’s behalf. On Call information will be supplied by The GCS Project. However, specific questions about the care you are receiving should be directed to your oncologist.
Another service of The GCS Project is helping patients locate physicians to perform in-person and virtual second opinions. The complexity of Gynecological Carcinosarcoma means a second opinion/consult can be extremely important. The goal of this service is to help patients and families find the best treatment for Gynecological Carcinosarcoma. There is no charge for these services, funded by generous gifts to The GCS Project.
Please call with your question to 833-4GCS-Hope (833-442-7464).
The GCS Project is dedicated to finding a cure for Gynecological Carcinosarcoma (aka MMMT), providing current scientifically valid information, and offering a place for the community impacted by this cancer to share stories and hope.
I am so incredibly proud to say that my mom is continuing to thrive, cancer-free. The words still seem foreign to me—‘cancer’ still pulls my heart to my throat, but… Read More »
Clinical trials are currently being offered at the University of Arkansas for Medical Sciences (UAMS). Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single… Read More »
Clinical trials are currently being offered at the University of Alabama at Birmingham. Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in… Read More »
Clinical trials are currently being offered at Medical University of South Carolina (MUSC) Health Care in Charleston SC. A Phase II/III Study of Paciltaxel/Carboplatin alone, or combined with either Trastuzumab… Read More »
